Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.11
IART's Cash to Debt is ranked lower than
55% of the 479 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. IART: 0.11 )
IART' s 10-Year Cash to Debt Range
Min: 0.09   Max: No Debt
Current: 0.11

Equity to Asset 0.45
IART's Equity to Asset is ranked higher than
55% of the 449 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. IART: 0.45 )
IART' s 10-Year Equity to Asset Range
Min: 0.32   Max: 0.95
Current: 0.45

0.32
0.95
Interest Coverage 2.98
IART's Interest Coverage is ranked lower than
58% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 231.38 vs. IART: 2.98 )
IART' s 10-Year Interest Coverage Range
Min: 1.58   Max: 9999.99
Current: 2.98

1.58
9999.99
F-Score: 6
Z-Score: 2.70
M-Score: -2.43
WACC vs ROIC
7.01%
3.99%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 7.06
IART's Operating margin (%) is ranked higher than
77% of the 463 Companies
in the Global Medical Devices industry.

( Industry Median: 6.11 vs. IART: 7.06 )
IART' s 10-Year Operating margin (%) Range
Min: -129.25   Max: 21.36
Current: 7.06

-129.25
21.36
Net-margin (%) 3.66
IART's Net-margin (%) is ranked higher than
73% of the 463 Companies
in the Global Medical Devices industry.

( Industry Median: 4.39 vs. IART: 3.66 )
IART' s 10-Year Net-margin (%) Range
Min: -249.02   Max: 31.32
Current: 3.66

-249.02
31.32
ROE (%) 4.96
IART's ROE (%) is ranked higher than
72% of the 448 Companies
in the Global Medical Devices industry.

( Industry Median: 5.76 vs. IART: 4.96 )
IART' s 10-Year ROE (%) Range
Min: -41.36   Max: 20.29
Current: 4.96

-41.36
20.29
ROA (%) 2.29
IART's ROA (%) is ranked higher than
73% of the 481 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. IART: 2.29 )
IART' s 10-Year ROA (%) Range
Min: -39.04   Max: 16.66
Current: 2.29

-39.04
16.66
ROC (Joel Greenblatt) (%) 10.36
IART's ROC (Joel Greenblatt) (%) is ranked higher than
75% of the 480 Companies
in the Global Medical Devices industry.

( Industry Median: 9.33 vs. IART: 10.36 )
IART' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -115.42   Max: 62.51
Current: 10.36

-115.42
62.51
Revenue Growth (3Y)(%) 2.10
IART's Revenue Growth (3Y)(%) is ranked higher than
69% of the 350 Companies
in the Global Medical Devices industry.

( Industry Median: 4.70 vs. IART: 2.10 )
IART' s 10-Year Revenue Growth (3Y)(%) Range
Min: -3.2   Max: 55.2
Current: 2.1

-3.2
55.2
EBITDA Growth (3Y)(%) 2.10
IART's EBITDA Growth (3Y)(%) is ranked higher than
76% of the 305 Companies
in the Global Medical Devices industry.

( Industry Median: 3.50 vs. IART: 2.10 )
IART' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -37.7   Max: 35.2
Current: 2.1

-37.7
35.2
EPS Growth (3Y)(%) 2.70
IART's EPS Growth (3Y)(%) is ranked higher than
76% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. IART: 2.70 )
IART' s 10-Year EPS Growth (3Y)(%) Range
Min: -31.7   Max: 27.1
Current: 2.7

-31.7
27.1
» IART's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

IART Guru Trades in Q1 2014

Robert Olstein 49,000 sh (New)
Steven Cohen 46,100 sh (New)
Richard Snow 64,675 sh (+4.15%)
David Dreman 118,500 sh (+3.13%)
Ken Fisher 574,215 sh (-1.88%)
Paul Tudor Jones 7,700 sh (-37.4%)
» More
Q2 2014

IART Guru Trades in Q2 2014

Jim Simons 7,530 sh (New)
Richard Snow 97,390 sh (+50.58%)
Robert Olstein 55,000 sh (+12.24%)
David Dreman 115,951 sh (-2.15%)
Ken Fisher 532,225 sh (-7.31%)
Paul Tudor Jones 6,000 sh (-22.08%)
» More
Q3 2014

IART Guru Trades in Q3 2014

Joel Greenblatt 127,001 sh (New)
Paul Tudor Jones 7,700 sh (+28.33%)
Richard Snow 104,765 sh (+7.57%)
Ken Fisher 549,015 sh (+3.15%)
David Dreman 117,456 sh (+1.3%)
Robert Olstein 55,000 sh (unchged)
Jim Simons Sold Out
» More
Q4 2014

IART Guru Trades in Q4 2014

Jim Simons 5,400 sh (New)
Richard Snow 191,850 sh (+83.12%)
Paul Tudor Jones 9,361 sh (+21.57%)
David Dreman 124,944 sh (+6.38%)
Robert Olstein 57,000 sh (+3.64%)
Ken Fisher 537,125 sh (-2.17%)
Joel Greenblatt 18,049 sh (-85.79%)
» More
» Details

Insider Trades

Latest Guru Trades with IART

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Richard Snow 2014-12-31 Add 83.12%0.14%$46.77 - $54.38 $ 60.5222%191850
Joel Greenblatt 2014-12-31 Reduce -85.79%0.05%$46.77 - $54.38 $ 60.5222%18049
Joel Greenblatt 2014-09-30 New Buy0.06%$46.18 - $50.7 $ 60.5224%127001
Richard Snow 2014-06-30 Add 50.58%0.05%$43.99 - $47.75 $ 60.5233%97390
Robert Olstein 2014-03-31 New Buy0.31%$44.52 - $49.5 $ 60.5228%49000
Richard Snow 2013-12-31 Add 28.22%0.03%$41.03 - $47.84 $ 60.5235%62095
David Dreman 2013-09-30 Reduce -72.05%0.3%$36.75 - $42.48 $ 60.5254%100464
Richard Snow 2013-09-30 Add 23.86%0.02%$36.75 - $42.48 $ 60.5254%48430
Richard Snow 2013-06-30 New Buy0.07%$31.84 - $39.42 $ 60.5269%39100
Ken Fisher 2013-06-30 Add 20.21%0.01%$31.84 - $39.42 $ 60.5269%606415
David Dreman 2013-03-31 New Buy0.44%$38.97 - $44.11 $ 60.5247%423916
Richard Snow 2013-03-31 Sold Out 0.26%$38.97 - $44.11 $ 60.5247%0
Joel Greenblatt 2012-12-31 Sold Out 0.03%$35.99 - $41.72 $ 60.5257%0
Ken Fisher 2012-12-31 Add 22.43%0.01%$35.99 - $41.72 $ 60.5257%451720
Richard Snow 2012-12-31 Add 22.78%$35.99 - $41.72 $ 60.5257%11805
Joel Greenblatt 2012-09-30 New Buy0.03%$35.71 - $42.27 $ 60.5255%10255
Richard Snow 2012-09-30 Reduce -50.04%0.02%$35.71 - $42.27 $ 60.5255%9615
Richard Snow 2012-06-30 Add 26.45%0.01%$31.76 - $37.82 $ 60.5275%19245
Richard Snow 2012-03-31 New Buy0.03%$23.22 - $35.74 $ 60.52110%15220
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 58.00
IART's P/E(ttm) is ranked higher than
74% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 137.90 vs. IART: 58.00 )
IART' s 10-Year P/E(ttm) Range
Min: 16.87   Max: 88.79
Current: 58

16.87
88.79
Forward P/E 17.09
IART's Forward P/E is ranked higher than
93% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. IART: 17.09 )
N/A
PE(NRI) 59.60
IART's PE(NRI) is ranked higher than
77% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 115.50 vs. IART: 59.60 )
IART' s 10-Year PE(NRI) Range
Min: 16.78   Max: 88.3
Current: 59.6

16.78
88.3
P/B 2.90
IART's P/B is ranked higher than
74% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 4.25 vs. IART: 2.90 )
IART' s 10-Year P/B Range
Min: 1.33   Max: 6.04
Current: 2.9

1.33
6.04
P/S 2.20
IART's P/S is ranked higher than
74% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 3.71 vs. IART: 2.20 )
IART' s 10-Year P/S Range
Min: 0.88   Max: 5.79
Current: 2.2

0.88
5.79
PFCF 52.90
IART's PFCF is ranked higher than
80% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. IART: 52.90 )
IART' s 10-Year PFCF Range
Min: 6.81   Max: 260.42
Current: 52.9

6.81
260.42
POCF 25.83
IART's POCF is ranked higher than
81% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 75.76 vs. IART: 25.83 )
IART' s 10-Year POCF Range
Min: 5.96   Max: 36.72
Current: 25.83

5.96
36.72
EV-to-EBIT 39.52
IART's EV-to-EBIT is ranked higher than
78% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 75.34 vs. IART: 39.52 )
IART' s 10-Year EV-to-EBIT Range
Min: -253.4   Max: 657.6
Current: 39.52

-253.4
657.6
Shiller P/E 51.20
IART's Shiller P/E is ranked higher than
83% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. IART: 51.20 )
IART' s 10-Year Shiller P/E Range
Min: 17.88   Max: 218.07
Current: 51.2

17.88
218.07
Current Ratio 4.20
IART's Current Ratio is ranked higher than
82% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 2.48 vs. IART: 4.20 )
IART' s 10-Year Current Ratio Range
Min: 0.81   Max: 18.27
Current: 4.2

0.81
18.27
Quick Ratio 2.32
IART's Quick Ratio is ranked higher than
75% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 1.88 vs. IART: 2.32 )
IART' s 10-Year Quick Ratio Range
Min: 0.46   Max: 17.09
Current: 2.32

0.46
17.09
Days Inventory 230.37
IART's Days Inventory is ranked higher than
62% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 165.69 vs. IART: 230.37 )
IART' s 10-Year Days Inventory Range
Min: 112.73   Max: 229.69
Current: 230.37

112.73
229.69
Days Sales Outstanding 51.87
IART's Days Sales Outstanding is ranked higher than
87% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 79.24 vs. IART: 51.87 )
IART' s 10-Year Days Sales Outstanding Range
Min: 50.48   Max: 80.8
Current: 51.87

50.48
80.8

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 2.00
IART's Price/DCF (Projected) is ranked higher than
90% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. IART: 2.00 )
IART' s 10-Year Price/DCF (Projected) Range
Min: 0.69   Max: 8.21
Current: 2

0.69
8.21
Price/Median PS Value 1.20
IART's Price/Median PS Value is ranked higher than
75% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 1.47 vs. IART: 1.20 )
IART' s 10-Year Price/Median PS Value Range
Min: 0.63   Max: 5.58
Current: 1.2

0.63
5.58
Earnings Yield (Greenblatt) 2.50
IART's Earnings Yield (Greenblatt) is ranked higher than
74% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. IART: 2.50 )
IART' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 8.6
Current: 2.5

0.2
8.6
Forward Rate of Return (Yacktman) -15.07
IART's Forward Rate of Return (Yacktman) is ranked higher than
61% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: 4.93 vs. IART: -15.07 )
IART' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -17.9   Max: 1210.3
Current: -15.07

-17.9
1210.3

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:IL3.Germany,
Integra Lifesciences Holdings Corp was incorporated in Delaware in 1989. The Company develops, manufactures and market cost-effective surgical implants and medical instruments. Its products are used mainly in neurosurgery, extremity reconstruction, orthopedics and general surgery. The Company sells its products directly through various sales forces and through various distribution channels. The Company currently manufactures and sells its products in five reportable business segments: U.S. Neurosurgery, U.S. Extremities, U.S. Instruments, U.S. Spine and Other, and International. Its U.S. Neurosurgery sales organization sells a full line of products specifically for neurosurgery and neuro critical care. The Company has products for each step of a cranial procedure and the care of the patient after surgery. Its key products include dural repair products, tissue ablation equipment, intracranial monitoring equipment, cranial stabilization equipment, and cerebral spinal fluid management devices. It sells equipment used in the neurosurgery operating room and neurosurgery intensive care unit. It sells its products through directly employed sales representatives. U.S. Extremities; the Company define extremity reconstruction to mean the repair of soft tissue and the orthopedic reconstruction of bone in the foot, ankle and leg below the knee, and the hand, wrist, elbow and shoulder. Its key products include bone and joint fixation devices, implants and instruments for osteoarthritis, rheumatoid arthritis, wrist and shoulder arthroplasty, carpal tunnel syndrome, and cubital tunnel syndrome. Other key products include its regenerative medicine devices for the treatment of acute and chronic wounds, peripheral nerve repair and protection and tendon repair, and bone graft substitutes. The Company sells its products through a direct sales organization and through specialty distributors focused on their respective surgical disciplines. Its U.S. Instruments business portfolio includes over 60,000 instrument patterns and surgical products, including hospitals, surgery centers, and physician, dental and veterinary offices. In addition to selling hand-held instruments, it sells surgical headlight systems and table-mounted retractors. Its brands includes Jarit, Miltex, Padgett, Ruggles, Luxtec and Omni-Tract. The Company's U.S. Spine and Other segment offers comprehensive spinal fusion technologies that surgeons use along the full length of the spine, as well as differentiated offering of related orthobiologics. This segment also includes private-label sales of a broad set of its regenerative medicine technologies. The International segment sells similar products, but they are managed through Europe, Middle East and Africa, Latin/South America, Asia-Pacific, Australia, New Zealand and Canada. The Company's trademarks include AccuDrain, Accell, Accell Evo3, Advansys, Atoll , Ascension, Bold, Budde, Buzz , Camino, CRW, Coral, CUSA, Daytona, DenLite, Dur
» More Articles for IART

Headlines

Articles On GuruFocus.com
WEEKLY CFO SELLS HIGHLIGHT: LMT, WCG, GRPN, IART, CNK Aug 26 2013 
Integra LifeSciences Holdings Corp. (IART) EVP, Finance & Admin & CFO John B Iii Henneman sells 10,0 Mar 09 2011 
Integra LifeSciences Holdings Corp. (IART) CEO Stuart Essig sells 125,100 Shares Mar 08 2011 
Integra LifeSciences Holdings Corp. (IART) EVP, Finance & Admin & CFO John B Iii Henneman sells 5,32 Dec 08 2010 
Integra LifeSciences Holdings Corp. (IART) CEO Stuart Essig sells 100,000 Shares Dec 03 2010 
Integra LifeSciences Holdings Corp. (IART) CEO Stuart Essig sells 100,000 Shares Nov 04 2010 
Integra LifeSciences Holdings Corp. (IART) EVP, Finance & Admin & CFO John B Iii Henneman sells 100, Nov 04 2010 
Integra LifeSciences Holdings Corp. Reports Operating Results (10-Q) Oct 28 2010 
Integra LifeSciences Holdings Corp. Reports Operating Results (10-Q) Jul 29 2010 
Integra LifeSciences Holdings Corp. Reports Operating Results (10-Q) May 03 2010 

More From Other Websites
Integra (IART) Rides High on Solid Q4, DuraSeal Product Line - Analyst Blog Mar 18 2015
INTEGRA LIFESCIENCES HOLDINGS CORP Financials Mar 05 2015
10-K for Integra LifeSciences Holdings Corp. Mar 02 2015
INTEGRA LIFESCIENCES HOLDINGS CORP Files SEC form 10-K, Annual Report Feb 27 2015
Integra Lifesciences Tops Q4 Earnings, Revenues; Up Y/Y - Analyst Blog Feb 25 2015
Integra tops Street 4Q forecasts Feb 24 2015
Integra tops Street 4Q forecasts Feb 24 2015
Integra LifeSciences Holdings Corp Earnings Call scheduled for 8:30 am ET today Feb 24 2015
Q4 2014 Integra LifeSciences Holdings Corp Earnings Release - Before Market Open Feb 24 2015
INTEGRA LIFESCIENCES HOLDINGS CORP Files SEC form 8-K, Results of Operations and Financial... Feb 24 2015
Integra LifeSciences Reports Fourth Quarter 2014 Financial Results Feb 24 2015
INTEGRA LIFESCIENCES HOLDINGS CORP Files SEC form 8-K, Change in Directors or Principal Officers Feb 20 2015
Integra LifeSciences to Participate in the Raymond James Institutional Investors Conference,... Feb 20 2015
Integra LifeSciences to Participate in the Raymond James Institutional Investors Conference,... Feb 20 2015
Marc H. Morial, President and CEO of the National Urban League, Will Speak at Integra LifeSciences... Feb 18 2015
Marc H. Morial, President and CEO of the National Urban League, Will Speak at Integra LifeSciences... Feb 18 2015
Integra LifeSciences to Participate in the RBC Capital Markets' Global Healthcare Conference Feb 09 2015
Integra LifeSciences to Participate in the RBC Capital Markets' Global Healthcare Conference Feb 09 2015
Integra LifeSciences Announces Submission of a Premarket Approval Supplement Application for the... Feb 03 2015
INTEGRA LIFESCIENCES HOLDINGS CORP Files SEC form 8-K, Change in Directors or Principal Officers,... Jan 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK